Clinical Trial Update: Efficacy and Safety Study of Lucentis (Ranibizumab) and Visudyne (Verteporfin) Combination Therapy in Neovascular AMD [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the efficacy and safety of combining ranibizumab (Lucentis) with verteporfin (Visudyne) for neovascular age-related macular degeneratio…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neovascular Age-related Macular Degeneration

Drugs mentioned

• Lucentis (ranibizumab)
• Visudyne (verteporfin)

Snippet

Sponsor: Fondazione G.B. Bietti, IRCCS | Conditions: Neovascular Age Related Macular Degeneration | Phase 2 | Status: COMPLETED